Skip to Main Content

Paper Details

Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia.
Mol Cancer Ther
4
2022
-internal tandem duplication, AML, ASXL1, Acute Myeloid Leukemia, CG-806, FLT3, FLT3 kinase domain, FLT3-internal tandem duplication, Luxeptinib, NPM1, RAS, SEM, SRSF2, TP53, WT FLT3, acute myeloid leukemia, antitumor, dogs, isocitrate, isocitrate dehydrogenase-1/2, luxeptinib, mice, myelodysplastic/myeloproliferative neoplasms, myeloid malignancies, myelosuppression, patient, patients, xenograft AML model
Animals, Dogs, Humans, Leukemia, Myeloid, Acute, Mice, Mutation, Protein Kinase Inhibitors, Signal Transduction, fms-Like Tyrosine Kinase 3
Author NameAffiliation
William G Rice
Stephen B HowellDepartment of Medicine and the Moores Cancer Center, University of California
Hongying Zhang
Nasrin Rastgoo
Andrea Local
Andrea Local
Stephen E KurtzKnight Cancer Institute, Oregon Health & Science University
Stephen E KurtzOregon Health & Science University
Pierrette LoKnight Cancer Institute, Oregon Health & Science University
Pierrette LoOregon Health & Science University
Daniel BottomlyKnight Cancer Institute, Oregon Health & Science University
Daniel BottomlyOregon Health & Science University
Beth WilmotKnight Cancer Institute, Oregon Health & Science University
Beth WilmotOregon Health & Science University
Shannon K McWeeneyKnight Cancer Institute, Oregon Health & Science University
Shannon K McWeeneyOregon Health & Science University
Brian J DrukerKnight Cancer Institute, Oregon Health & Science University
Brian J DrukerOregon Health & Science University
Jeffrey W TynerKnight Cancer Institute, Oregon Health & Science University
Jeffrey W TynerOregon Health & Science University
Jeffrey W TynerOregon Health & Science University
  • 1 - 21

Datasets

Release 1.2